Lucid Diagnostics Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LUCD$0.42+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets: | ||
| Current assets: | ||
| Cash | $22,358 | $18,896 |
| Accounts receivable | 45 | 45 |
| Inventory | 341 | 278 |
| Prepaid expenses, deposits, and other current assets | 2,404 | 2,854 |
| Total current assets | 25,148 | 22,073 |
| Fixed assets, net | 1,062 | 1,334 |
| Operating lease right-of-use assets | 2,637 | 1,307 |
| Intangible assets, net | 736 | 1,424 |
| Other assets | 1,132 | 1,132 |
| Total assets | $30,715 | $27,270 |
| Liabilities, Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,241 | $1,146 |
| Accrued expenses and other current liabilities | 2,829 | 3,841 |
| Operating lease liabilities, current portion | 854 | 1,106 |
| Senior Secured Convertible Notes - at fair value | 18,600 | 13,950 |
| Due To: PAVmed Inc. - MSA Fee and operating expenses | — | 9,339 |
| Total current liabilities | 23,524 | 29,382 |
| Operating lease liabilities, less current portion | 1,800 | 199 |
| Total liabilities | 25,324 | 29,581 |
| Commitments and contingencies | - | - |
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series B and Series B-1 Convertible Preferred Stock, issued and outstanding 54,419 at December 31, 2024 and Series A and Series A-1 Convertible Preferred Stock, shares issued and outstanding 18,625 at December 31, 2023 | 54,419 | 18,625 |
| Common stock, $0.001 par value, 300,000,000 and 200,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 63,071,950 and 42,329,864 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 63 | 42 |
| Additional paid-in capital | 154,675 | 129,763 |
| Accumulated deficit | (203,766) | (150,741) |
| Total Stockholders’ Equity (Deficit) | 5,391 | (2,311) |
| Total Liabilities and Stockholders’ Equity (Deficit) | $30,715 | $27,270 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.